Skip to main content
Blood logoLink to Blood
. 2016 May 3;127(25):3133–3141. doi: 10.1182/blood-2015-10-636480

Acquired von Willebrand syndrome associated with left ventricular assist device

Angelo Nascimbene 1, Sriram Neelamegham 2, O H Frazier 3, Joel L Moake 3,4, Jing-fei Dong 5,6,
PMCID: PMC4920020  PMID: 27143258

Abstract

Left ventricular assist devices (LVAD) provide cardiac support for patients with end-stage heart disease as either bridge or destination therapy, and have significantly improved the survival of these patients. Whereas earlier models were designed to mimic the human heart by producing a pulsatile flow in parallel with the patient’s heart, newer devices, which are smaller and more durable, provide continuous blood flow along an axial path using an internal rotor in the blood. However, device-related hemostatic complications remain common and have negatively affected patients’ recovery and quality of life. In most patients, the von Willebrand factor (VWF) rapidly loses large multimers and binds poorly to platelets and subendothelial collagen upon LVAD implantation, leading to the term acquired von Willebrand syndrome (AVWS). These changes in VWF structure and adhesive activity recover quickly upon LVAD explantation and are not observed in patients with heart transplant. The VWF defects are believed to be caused by excessive cleavage of large VWF multimers by the metalloprotease ADAMTS-13 in an LVAD-driven circulation. However, evidence that this mechanism could be the primary cause for the loss of large VWF multimers and LVAD-associated bleeding remains circumstantial. This review discusses changes in VWF reactivity found in patients on LVAD support. It specifically focuses on impacts of LVAD-related mechanical stress on VWF structural stability and adhesive reactivity in exploring multiple causes of AVWS and LVAD-associated hemostatic complications.

A brief history and clinical applications of LVAD

The first ventricular assist device (VAD) was implanted by Michael E. Debakey in 1966 at the Methodist Hospital in Houston, Texas. The interest in developing a device for artificially supporting the circulation was further increased by the first total artificial heart implantation, performed by Denton A. Cooley in Houston on April 4, 1969.1 In 1986, O. H. Frazier and his colleagues began implanting the first generation of pneumatic pulsatile LVADs (the Heartmate 1000 IP) to improve end-organ perfusion in candidates for heart transplant.2 The patients with LVAD implants experienced significant improvements in long-term survival. The first continuous-flow LVAD—the Hemopump—was subsequently implanted in 1988.3 It was followed by successful implantations of the HeartMate XVE in 1991,4 the Jarvick 2000 in 2000,5 and the HeartMate2 (Figure 1) in 2003 by O. H. Frazier and his colleagues at St. Luke’s Hospital in Houston, Texas.6 Continuous-flow LVADs are designed to provide blood flow of up to 10 L/min by generating a continuous blood flow from the inlet through the revolving impeller to the outlet. They energize blood flow throughout the cardiac cycle, thereby activating the normally passive flow of diastole. This continuous and unidirectional flow allows for a simplified device design and a smaller size, because it obviates the need for unidirectional valves.

Figure 1.

Figure 1

Schematic illustration of an implanted continuous-flow HeartMate2 LVAD (with permission from Thoratec Corporation).

The axial continuous-flow HeartMate2 is currently the device approved by the U.S. Food and Drug Administration (FDA) for both bridge-to-transplant (BTT)7 and destination therapy (DT).8 It has been implanted in >15 000 patients worldwide.9 The centrifugal continuous-flow Heartware HVAD is an intrapericardial pump with an impeller suspended by a passive magnetic and hydrodynamic bearing that produces contact-free rotation (FDA approved for BTT10).

Heart failure is a severe medical condition affecting more than 5 million individuals and it is a leading cause of death in the US.11 Cardiac transplantation remains a valid option in the treatment of these patients. However, only 2000 to 2500 transplants are performed each year because of limited organ availability. More than 4000 patients are currently on the waiting list (www.unos.org/data/transplant-trends/#waitlists_by_organ), and this number is expected to grow substantially because of our increasingly aging population. Patients on the waiting list have a significantly higher rate of mortality than those who receive the implants. LVADs were introduced as a rescue strategy for patients dying while on the heart transplant waiting list. They were used as a temporary solution until a donor heart could be transplanted (BTT).2 The early positive results of BTT led the FDA to approve the use of LVADs as an alternative to heart transplants, serving as a destination therapy.12 In some cases, LVADs have been shown to restore sufficient cardiac function and end-organ perfusion that patients who were previously ineligible for heart transplants eventually met transplantation criteria (bridge to decision). In rare cases, patients have had their LVADs successfully explanted (bridge to recovery).13,14 All surgical interventions alter internal anatomy to a condition that is not normal, but is better than the diseased condition it corrects. In the case of LVAD, the alteration is to the blood flow. Although patients have survived with normal activity for >10 years without a pulse, a LVAD can result in complications in some patients related to the unique levels and patterns of blood flow created by the device.

LVAD-related hemostatic complications

Major LVAD-associated complications include bleeding, neurologic dysfunction (transient ischemic attack and stroke), pump thrombosis, infection, right ventricular failure, and aortic regurgitation as codified by the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS).15 The registry collects clinical data on mechanical circulatory support devices from index hospitalization through follow-up evaluation on 16 268 patients from 163 centers (as of August 2015).

Neurologic dysfunction, pump thrombosis, and bleeding are common hemostatic complications. A stroke rate of 0.064 event per patient per year (EPPY) was reported in a 7.5-year study of 230 patients implanted with the HeartMate2 as either BTT (80.4%) or DT (19.6%),16 significantly higher than the 0.013 to 0.035 EPPY reported for patients with advanced heart failure.8,17 The stroke rates for the Heartware were 0.11 and 0.09 EPPY for ischemic and hemorrhagic stroke, respectively.10 LVAD-supported patients who experienced stroke had twice the risk of death as stroke-free patients.16

Pump thrombosis is usually located at the bearing of the device and presents at inspection as a chronic fibrous pannus formation that responds poorly to thrombolytic therapy. Pump exchange is the treatment of choice.18 The incidence of pump thrombosis with the HeartMate2 was 2% to 4%, with 0.03 EPPY in the first year in a BTT trial7; and 0.024 EPPY over a 2-year period in a DT trial.8

LVAD-associated bleeding is the most frequent complication, occurring in 19% to 40% of patients on HeartMate2 support.19,20 INTERMACS defines LVAD-related bleeding as episodes of internal or external bleeding that result in death, reoperation, hospitalization, or transfusion of packed red blood cells (>4 U in the first 7 days, or any units >7 days after the implant). Bleeding within 7 days is primarily caused by surgery and the use of anticoagulants after the LVAD implantation. However, nonsurgical bleeding that occurs later has emerged as a major challenge to the recovery of patients on LVAD support. The mean time for nonsurgical bleeding and the rate of recurrent bleeding after LVAD implant varies significantly among published reports, ranging from 10 to 154 days,21-23 and 9.3% to 60%, respectively.22,24,25 Gastrointestinal (GI) bleeding and epistaxis are more common than mediastinum/thorax and intracranial bleeding.26-30 The incidence of GI bleeding increased significantly, from 0.068 EPPY for pulsatile LVADs to 0.63 EPPY for continuous-flow LVADs.31

Patients with clinical GI bleeding are treated in consultation with gastroenterologists, undergoing colonoscopy, upper endoscopic evaluation, and/or small bowel capsule endoscopy. In the presence of persistent GI bleeding with negative endoscopic findings, a tagged red blood scan or angiography is recommended. Optimal anticoagulation levels and an antiplatelet regimen for patients on LVAD support is an active area of research. In the absence of evident pump dysfunction, current guidelines32 recommend holding anticoagulation and antiplatelet therapy in the presence of clinically significant bleeding. During this holding period, strict clinical follow-ups are imperative because of the increased risk for device malfunction, pump thrombosis, and ischemic stroke.32,33 The US-TRACE study found that recurrent bleeding was reported in as much as 52% of cases despite the reduction in antithrombotic therapy, suggesting that anticoagulation might be only partially responsible for the hemorrhagic complications in these patients.33 Anticoagulation and antiplatelet therapy can be reintroduced with careful monitoring when the bleeding episode has resolved. In the case of refractory bleeding, the indication for warfarin and target international normalized ratio should be re-evaluated depending on the bleeding severity and pump types.32 Octreotide and thalidomide have been reported as off-label adjuvants for controlling recurrent GI bleeding,34-36 but neither has been systematically studied for the treatment of LVAD-related bleeding. Thalidomide is also associated with an increased risk of thrombosis.25,37

Attempts have been made to operate a continuous-flow device at a lower speed to reduce shear stress and to reintroduce pulsatility. At a lower LVAD speed, the native heart may increase (transiently and in systole only) the total cardiac output with minimal stroke volume. This approach has not been fully validated and may limit the amount of LVAD support to the native heart. New-generation devices have incorporated operational algorithms to introduce cardiac output variations over several cardiac cycles. These algorithms aim at simulating an arterial pulse pressure and, if effective, may reduce LVAD-induced bleeding. Additional information related to the clinical presentation and managements of LVAD-associated hemostatic defects is discussed by Susen et al in a recent review.38 In this review, we focus on the underlying mechanisms of LVAD-associated VWF abnormalities and their contributions to clinical bleeding.

GI bleeding is often found at the site of an arteriovenous malformation (AVM).39,40 There are at least 2 theories regarding how an AVM is formed. One is that high intraluminal pressure causes reflective and localized smooth muscle relaxation and arteriovenular dilation.39 The other is that intestinal hypoperfusion resulting from reduced pulse pressure leads to regional hypoxia, vascular dilation, and subsequent angiodysplasia.26 However, neither theory explains why the AVM is primarily formed in the GI track. Nevertheless, it was the association of AVM with GI bleeding that led to the hypothesis that LVAD-associated bleeding is similar to aortic valve stenosis (Heyde syndrome)41 in that it is caused by the deficiency of the adhesive ligand VWF and thus is often called acquired von Willebrand syndrome (AVWS).31,42,43

Biology of von Willebrand factor

VWF mediates platelet tethering to the subendothelial matrix at sites of vascular injury to initiate hemostasis. It also protects the coagulation factor VIII (FVIII) against proteolytic degradation by forming a VWF–FVIII complex in the circulation.44 As an acute-phase reactant, VWF synthesis and secretion is rapidly and significantly increased in response to inflammatory and ischemic insults. Elevated levels of VWF antigen and/or adhesion to platelets are, therefore, widely used as markers for endothelial perturbation and propensity for thrombosis and thromboembolism.

VWF is synthesized in megakaryocytes and endothelial cells as a single-chain propolypeptide of 2813 amino acids.44 A mature VWF monomer contains 4 types of repeated domains in the order of D1-D2-D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (Figure 2A). The D′ and D3 domains mediate VWF multimerization and FVIII binding.45-48 The A1 and A3 domains contain the binding sites for the platelet glycoprotein (GP) Ib-IX-V complex and the subendothelial collagen, respectively. The A2 domain contains the Tyr1605-Met1606 peptide bond that is cleaved by a disintegrin and metalloprotease with thrombospondin type 1 repeat 13 (ADAMTS-13).49-51 The C domain contains an RGD sequence that interacts with integrins. Free thiols in the C domain are also involved in the shear-induced lateral association of VWF multimers to form highly adhesive fibrils.52,53

Figure 2.

Figure 2

VWF domain structure and potential lateral association. (A) VWF domain structure. ProVWF forms disulfide-linked dimers (B) that further multimerize covalently to multimers in the Golgi (C). These multimers are packaged in the storage granule Weibel-Palade body of endothelial cells (D), where the multimerization process is likely to continue, but factors that regulate its rate and termination remain largely unknown. The stored VWF multimers are released from endothelial cells that are activated by inflammatory stimuli. These newly released VWF multimers form fibrillary meshes that capture platelets (E) and are proteolytically released from the surface of endothelial cells by ADAMTS-13 (F).

Once synthesized, pro-VWF monomers first dimerize through C-terminal disulfide bonds.54 A variable number of dimers then multimerize through the N-terminal disulfide bonds55-58 after the proteolytic removal of a 741-amino-acid propeptide (Figure 2B-C).54,59-62 The newly synthesized VWF multimers are either constitutively released or stored in the Weibel-Palade bodies (Figure 2D) of endothelial cells and the α-granules of megakaryocytes and platelets.63,64 VWF multimers stored in these granules are enriched in large and ultralarge (UL) forms that are released from activated endothelial cells.62,63,65-67 Newly released VWF multimers can be anchored to the surface of endothelial cells to form elongated and membrane-anchored VWF fibrils that are cleaved by ADAMTS-13 and released from the cells (Figure 2E).68,69 It is because of this unique structure that VWF adhesive activity is determined not only by antigen level, but also by the size of multimers, with large and UL multimers being most active in hemostasis and thrombosis/thromboembolism, respectively.56,70 This large and flexible structure also renders VWF prone to undergoing changes in conformation and adhesive activity in response to fluidic mechanical forces that are closely associated with LVAD implantation.

Regulation of VWF by physical forces

The most drastic change brought by a continuous LVAD is the conversion of a pulsatile flow of blood to a continuous flow with a significantly elevated shear rate and stress, not only in the device, but also systemically. An increase in fluid shear stress above certain thresholds is known to alter the structure of VWF multimers to induce VWF cleavage by ADAMTS-13 and also VWF binding to platelets (Figure 3).71-73

Figure 3.

Figure 3

Shear-induced platelet activation. Platelets in diluted PRP or whole blood subjected to fluid shear in a cone-plate viscometer abruptly undergo activation above a critical wall shear stress of 8-10 Pa (arrow). Inset shows that this activation is a strong function of the mechanical force applied on the platelet GP Ibα by the VWF that is bound to it. Here, doubling media viscosity more than doubles the extent of cell activation (adapted from Shankaran et al71).

Among the continuous-flow devices, axial-flow LVADs have a high impeller speed that results in a high local shear rate and stress. Platelets in this device experience stresses of >10 Pa (1 Pa = 1 N/m2 = 10 dynes/cm2) during their passage, and some are exposed to stress as high as 600 Pa (Table 1).74-77 A centrifugal pump has a lower impeller velocity than an axial pump and lower wall shear stress throughout the device.76,77 Regions of high, nonphysiologic flow are formed in axial pumps with an estimated wall shear stress of >10 Pa, as is found in most of the devices.76,78 However, a recent study that compared the performance of centrifugal and axial-flow LVADs in 102 patients showed an equivalent loss of large VWF multimers and similar incidences of bleeding and thromboembolic events.79

Table 1.

Typical range of wall shear rates and stresses in blood vessels

Blood vessel Shear rate (/s) Shear stress (Pa)
Large arteries* 300-800 1.4-3.6
Arterioles* 450-1600 2-7.2
Veins* 15-200 0.07-0.9
Stenotic vessels* 800-10 000 3.6-45
Axial flow LVAD 600
Centrifugal flow LVAD 150-230
*

Values for different vessels are adapted from Kroll et al74; mean wall shear rate/stress values are presented. Peak values could be higher.

Present peak value in typical devices based on experimental measurements and computational fluid dynamics calculations (blood flow rate was 4-7 L/min). These values were summarized from Girdhar et al,75 Selgrade and Truskey,76 and Fraser et al.77

A growing body of evidence suggests that a local shear stress in excess of 10 Pa can result in the application of forces >∼10-15 pN (piconewton = 10−12 N), which induces VWF to undergo conformational transition from a “resting” to an “active” state80 and to self-associate.71,81 Similar magnitudes of fluidic stress also promote the proteolysis by ADAMTS-13 of the cryptic Tyr1605-Met1606 peptide bond in the VWF A2-domain.72,73 In this regard, whereas VWF coexists with ADAMTS-13 in plasma, it remains mostly uncleaved unless the Tyr1605-Met1606 scissile bond is exposed by mechanical forces in solution82 or upon binding to a platelet,83 or collagen,84 or being anchored to endothelial cells.68 The force required for inducing the cleavage lies in the range of 7 to 14 pN that unfolds the VWF A2 domain.72 A slightly larger force is needed to unfold and cleave a recombinant VWF A1-A2-A3 tri-domain.73 More importantly, this magnitude of force also induces and strengthens VWF binding to platelet GP Ibα.85,86 These opposing effects of high shear stress on VWF raise the important question of which of the 2 processes (excessive cleavage by ADAMTS-13 or shear-induced binding to platelets) occurs predominantly in an LVAD-driven circulation and how the 2 processes are differentially regulated by confounding factors.

Two scenarios should be considered in elucidating the effects of mechanical forces on adhesive reactivity and cleavage when VWF is (1) subjected to shear stress in solution, because this can occur during its passage through an LVAD; and (2) attached to the biomaterials that compose the prosthetic device or to the surface of platelets or endothelial cells.

In the first scenario, VWF in flowing blood experiences periodic variations in shear forces as it tumbles through the circulation. Shear forces are at their maximal level when the protein is oriented either parallel or perpendicular to the direction of flow, and stretching forces that pull the molecule apart are at their maximum level when the protein is oriented at 45° to the flow direction.87 These oscillatory force cycles repeat every ∼10 msec when the applied shear stress is 10 Pa, with increasing shear stress proportionally decreasing the duration of force oscillation.87 Biophysical calculations based on protein geometry show that the maximal force applied to VWF during these periodic cycles is tensile in nature (rather than shear). This tensile force tends to stretch or unfold VWF multimers87 and is maximal at the geometric center of VWF when it is oriented at 45° to the direction of flow. For a VWF protomer composed of two C-terminal dimerized VWF monomers, this peak tensile force is estimated to be Fp ∼0.01 · τ, where Fp is the applied force in pN and τ is the applied shear stress in Pa.87,88 Extending this estimate to multimeric VWF with Np dimeric repeats stretched into a maximally extended linear structure, the force applied to multimeric VWF is approximately Fmulti = Fp · Np2/2.72 This derivation assumes that the force applied at the center of a fully extended VWF multimer can be estimated by summing up the hydrodynamic forces on VWF doublets that were located more outward, toward the ends of the VWF multimer. Thus, at a shear stress of 10 Pa, the peak force on a 20-mer VWF multimer would be 20 pN (0.01 × 10 × (20)2/2) applied at the midpoint of the molecule.

Studies using single-molecule fluorescence microscopy,80 small-angle neutron scattering (SANS),89 and fluorescence spectroscopy90 have suggested that VWF can undergo structural transitions under shear stresses of ∼8-10 Pa. More specifically, the fluorescence microscopy reveals a large-scale extension of VWF, with end-to-end lengths of up to 10 μm at a shear stress of >5 Pa.80 At shear stresses of >8 Pa, VWF multimers also bind to a fluorescent probe bis-ANS that recognizes nonpolar cavities exposed on the sheared protein.90 These hydrophobic pockets gradually become buried over a period of time ranging from minutes to hours, suggesting that once unfolded, proteins may not recover their native conformation immediately upon the removal of shear stress. This delayed recovery is also demonstrated in the long relaxation time of VWF fibrils returning back to their original conformation after a mechanical force applied to induce domain-unfolding was removed.52,81 A shear stress of ∼8 Pa is also necessary for VWF self-association in solution as measured using light-scattering.71 Similar magnitudes of forces enable the formation of VWF bundles or fibers in synthetic microvessels that are lined with endothelial cells.91 Thus, ∼8-10 Pa represents a critical shear threshold at which a number of investigators have noted protein structural changes measured using different techniques.

Stretching forces are also applied when VWF multimers form a bridge between 2 platelets that are tumbling together in a shear field.83,87 In this situation, the force applied to a VWF at a given shear rate would be 2 to 3 orders of magnitude greater than the force applied to free VWF in solution. Given the size of a typical human platelet, this force is estimated to be Fplat-plat (pN) ∼45 · τ.87,88 Thus, the bridging of 2 platelets by VWF at 10 Pa would result in the application of a ∼450 pN force on both the VWF multimers and the platelet GP Ibα. This force estimate may explain why VWF cleavage by ADAMTS-13 is enhanced when the VWF multimers are platelet-bound.83 The formation of VWF-crosslinked platelets through supraphysiologic shear in an LVAD would, therefore, increase force application, leading to VWF-mediated mechanotransduction/platelet activation and VWF proteolysis.71,92,93

In the second scenario, shear-driven VWF immobilization on such substrates as collagen and the biomaterial surfaces of LVADs could result in changes to VWF conformation. This was originally demonstrated using atomic force microscopy on hydrophobic substrates in which the application of wall shear stress >3.5 Pa triggered VWF unfolding.94 Extended VWF fiber meshes have also been reported on collagen substrates at shear stresses >10 Pa.84,95 These extended VWF bundles may themselves be susceptible to cleavage by ADAMTS-13, because the attachment of platelets to the immobilized VWF further enhances the force applied to both VWF and GP Ibα. The force applied to platelet-bound VWF strings can be estimated at ∼76 τ pN.88 At 10 Pa, a 760-pN force would, therefore, be applied to both VWF and the attached platelet GP Ibα, triggering both platelet mechanotransduction that activates platelets and ADAMTS-13–mediated proteolysis. Overall, when the applied shear stress exceeds the physiologic range, as is found in an LVAD-driven circulation, biophysical processes are simultaneously triggered that together promote both VWF binding to GP Ibα (and subsequent platelet activation) and its proteolysis by ADAMTS-13.

Finally, Da et al report that free hemoglobin augments platelet adhesion and microthrombus formation on an extracellular matrix at high shear stresses in a GP Ib and VWF-dependent manner.96 Hemoglobin is also reported to sterically hinder ADAMTS-13–VWF interaction.97 These findings are relevant because hemolysis often occurs in patients on LVAD support and is associated with thrombotic events.98-101 They also raise an important question regarding the potential redox-regulation of VWF reactivity and cleavage by hemoglobin, which is often called a “biological Fenton’s reagent” for its strong oxidative activity (from the heme iron).102 Oxidative stress has indeed been shown to make VWF hyper-reactive, render them resistant to ADAMTS-13, and inhibit ADAMTS-13 activity.103-106 Some of redox-sensitive residues in VWF and ADAMTS-13 are exposed by the high shear stress104 found in the LVAD-driven circulation.

LVAD-associated AVWS

LVAD-associated AVWS has so far been defined by laboratory findings that plasma VWF from patients on LVAD support lacks large multimers (Figure 4)31,42,79,107-110 and has reduced activity in agglutinating lyophilized platelets (ristocetin cofactor activity, VWF:Rco) and in binding the collagen matrix (VWF:CB).31,79,107,108,111-115 These VWF defects are observed soon after LVAD implantation,42,43 rapidly resolve after LVAD explantation,109,111-113 and were not observed in heart transplant recipients,31,43 indicating their close association with the level and pattern of the LVAD-driven blood flow. The rapid loss of large VWF multimers and their quick recovery was also observed in a rabbit model of reversible arterial stenosis to alter blood flow.112

Figure 4.

Figure 4

VWF multimer found in patients on LVAD. Examples of VWF multimer patterns found in normal plasma pooled from 32 healthy subjects and in patients on LVAD support who developed myocardial infarction (Patient A), no complication (Patient B), and severe GI bleeding (Patient C). Samples were collected before LVAD implant (BL), 3 months after implant (3), and at the time of readmission for the clinical complications (E).

One widely held view is that the loss of VWF large multimers and reduction in VWF adhesive activity are caused by excessive cleavage of VWF by ADAMTS-13 under a persistently elevated level of shear stress in the LVAD-supported circulation. This shear-induced cleavage reduces VWF size and adhesive activity in a pattern similar to patients with type 2A VWD.31,79,107,108,116 However, this tentative mechanism has not been experimentally validated, and significant gaps remain. First, there is no direct evidence that VWF multimers are excessively cleaved by ADAMTS-13 in patients on LVAD support. Alternative VWF cleavage by other proteases such as the serine protease granzyme,117,118 plasmin,119 and Staphylococcus aureus V-8 protease,58,120 and its effect on VWF reactivity in a LVAD setting, have not been examined. For example, it has been shown that granzyme secreted from immune and cytotoxic lymphocytes in conditions of inflammation proteolytically reduces VWF adhesive activity117-119 and disrupts VWF–FVIII interaction.118 The serine protease plasmin cleaves VWF fibrils that are resistant to ADAMTS-13.119 Second, VWF antigen was significantly increased in all patients,79,108,109 a condition that is not common in patients with type 2 VWD.121,122 The question is whether the loss of large VWF multimers can be compensated for by an increase in VWF antigen. Third, the loss of large VWF multimers has been observed in nearly all patients, but only a small portion of them have clinically relevant bleeding. More importantly, neither the loss of large VWF multimers nor a reduced VWF:Rco activity is associated with bleeding, thrombosis, or the need for transfusion in patients on LVAD support.79,87,109,114,123 Although this lack of association may be attributed to clinical variations among patients, it is also possible that AVWS constitutes a baseline condition that has minimal clinical consequences on its own, and that requires a trigger or additive event to propagate bleeding and/or thrombosis in patients on LVAD support. Fourth, while it facilitates VWF cleavage by ADAMTS-13,72,73,82 a high fluid shear stress or a tensile force also unfolds VWF to bind and activate platelets,74,81,124-126 potentially leading to a consumptive deficiency in large VWF multimers, similar to patients with type 2B VWD. This shear-induced platelet aggregation depends on the attachment of large VWF multimers to GP Ibα and the activation of integrin αIIbβ3.125,127,128 This gain-of-function VWF phenotype can not only remove large VWF multimers from the circulation, but also occlude cerebral and GI microvessels, producing punctate injury, bleeding, and AVM. In this case, a patient with deficient large VWF multimers may be prone to thrombosis, not bleeding. If the theory of shear-induced platelet aggregation is to be credence, one may consider that shear- and/or oxidative stress-mediated VWF binding to platelets is effectively prevented in most patients by therapeutic agents that block platelet ADP receptors (clopidogrel) and/or integrin αIIbβ3 (tirofiban, eptifibatide).129,130 The patients who develop bleeding or thromboembolism may have an inadequate therapeutic blockade of platelets in terms of the dosage, type, or protocol used during their care. Furthermore, aspirin is widely used to inhibit platelet activation in patients on LVAD support, but has been found to be ineffective in vitro to prevent shear-induced and VWF-mediated aggregation of platelets.125 A distinction between excessive VWF cleavage (loss-of-function) and enhanced VWF binding to platelets (gain-of-function) may, therefore, provide further insights into the causes of LVAD-induced loss of large VWF multimers and its association with bleeding and thrombosis.

Conclusion

The evidence in support of the excessive cleavage of large VWF multimers by ADAMTS-13 as a primary cause of LVAD-associated bleeding remains circumstantial. A large body of clinical and laboratory evidence suggests that the LVAD-associated loss of large VWF multimers can also be caused by shear- and oxidative stress–induced VWF binding to platelets. This conjecture is consistent with a recent report that thromboembolic events were 7.4 times as likely to occur in LVAD patients who had experienced prior GI bleeding.121 Defining this phenotypic diversity may hold the key to understanding the contribution of AVWS to the bleeding and thrombotic complications associated with LVAD implantation. It may also be essential for devising effective preventative and therapeutic strategies for the debilitating complications.

Acknowledgments

This work is supported by National Institute of Health, National Heart, Lung, and Blood Institute grants HL77258 (S.N.), and HL71895 and HL125957 (J.-f.D.).

Authorship

A.N., S.N., and J.-f.D. conducted background research, and all authors wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Jing-fei Dong, BloodWorks Research Institute, 1551 Eastlake Ave East, Seattle, WA 98102; e-mail: jfdong@bloodworksnw.org.

Reference List

  • 1.Cooley DA, Liotta D, Hallman GL, Bloodwell RD, Leachman RD, Milam JD. Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol. 1969;24(5):723–730. doi: 10.1016/0002-9149(69)90460-3. [DOI] [PubMed] [Google Scholar]
  • 2.Frazier OH, Rose EA, McCarthy P, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg. 1995;222(3):327–336, discussion 336-338. doi: 10.1097/00000658-199509000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Frazier OH, Wampler RK, Duncan JM, et al. First human use of the Hemopump, a catheter-mounted ventricular assist device. Ann Thorac Surg. 1990;49(2):299–304. doi: 10.1016/0003-4975(90)90155-y. [DOI] [PubMed] [Google Scholar]
  • 4.Frazier OH. First use of an untethered, vented electric left ventricular assist device for long-term support. Circulation. 1994;89(6):2908–2914. doi: 10.1161/01.cir.89.6.2908. [DOI] [PubMed] [Google Scholar]
  • 5.Frazier OH, Gregoric ID, Delgado RM, et al. Initial experience with the Jarvik 2000 left ventricular assist system as a bridge to transplantation: report of 4 cases. J Heart Lung Transplant. 2001;20(2):201. doi: 10.1016/s1053-2498(00)00428-9. [DOI] [PubMed] [Google Scholar]
  • 6.Frazier OH, Delgado RM, III, Kar B, Patel V, Gregoric ID, Myers TJ. First clinical use of the redesigned HeartMate II left ventricular assist system in the United States: a case report. Tex Heart Inst J. 2004;31(2):157–159. [PMC free article] [PubMed] [Google Scholar]
  • 7.Miller LW, Pagani FD, Russell SD, et al. HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357(9):885–896. doi: 10.1056/NEJMoa067758. [DOI] [PubMed] [Google Scholar]
  • 8.Slaughter MS, Rogers JG, Milano CA, et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–2251. doi: 10.1056/NEJMoa0909938. [DOI] [PubMed] [Google Scholar]
  • 9.Kirklin JK, Naftel DC, Pagani FD, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495–1504. doi: 10.1016/j.healun.2015.10.003. [DOI] [PubMed] [Google Scholar]
  • 10.Aaronson KD, Slaughter MS, Miller LW, et al. HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125(25):3191–3200. doi: 10.1161/CIRCULATIONAHA.111.058412. [DOI] [PubMed] [Google Scholar]
  • 11.Lloyd-Jones D, Adams RJ, Brown TM, et al. WRITING GROUP MEMBERS; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667. [DOI] [PubMed] [Google Scholar]
  • 12.Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–1443. doi: 10.1056/NEJMoa012175. [DOI] [PubMed] [Google Scholar]
  • 13.Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355(18):1873–1884. doi: 10.1056/NEJMoa053063. [DOI] [PubMed] [Google Scholar]
  • 14.Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98(22):2383–2389. doi: 10.1161/01.cir.98.22.2383. [DOI] [PubMed] [Google Scholar]
  • 15. INTERMACS. Available at: http://www.uab.edu/medicine/intermacs/images/protocol_4.0/protocol_4.0_MoP/Appendix_A_INTERMACS_AE_Definitions_Final_06122015.docx.
  • 16.Harvey L, Holley C, Roy SS, et al. Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era. Ann Thorac Surg. 2015;100(2):535–541. doi: 10.1016/j.athoracsur.2015.02.094. [DOI] [PubMed] [Google Scholar]
  • 17.Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology. 2000;54(2):288–294. doi: 10.1212/wnl.54.2.288. [DOI] [PubMed] [Google Scholar]
  • 18.Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28(6):535–541. doi: 10.1016/j.healun.2009.02.015. [DOI] [PubMed] [Google Scholar]
  • 19.Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011;57(19):1890–1898. doi: 10.1016/j.jacc.2010.10.062. [DOI] [PubMed] [Google Scholar]
  • 20.Lahpor J, Khaghani A, Hetzer R, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37(2):357–361. doi: 10.1016/j.ejcts.2009.05.043. [DOI] [PubMed] [Google Scholar]
  • 21.Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Morgan JA. Factors determining post-operative readmissions after left ventricular assist device implantation. J Heart Lung Transplant. 2014;33(10):1041–1047. doi: 10.1016/j.healun.2014.05.009. [DOI] [PubMed] [Google Scholar]
  • 22.Marsano J, Desai J, Chang S, Chau M, Pochapin M, Gurvits GE. Characteristics of gastrointestinal bleeding after placement of continuous-flow left ventricular assist device: a case series. Dig Dis Sci. 2015;60(6):1859–1867. doi: 10.1007/s10620-015-3538-7. [DOI] [PubMed] [Google Scholar]
  • 23.Akhter SA, Badami A, Murray M, et al. Hospital Readmissions After Continuous-Flow Left Ventricular Assist Device Implantation: Incidence, Causes, and Cost Analysis. Ann Thorac Surg. 2015;100(3):884–889. doi: 10.1016/j.athoracsur.2015.03.010. [DOI] [PubMed] [Google Scholar]
  • 24.Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31(7):715–718. doi: 10.1016/j.healun.2012.02.015. [DOI] [PubMed] [Google Scholar]
  • 25.Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80(3):435–446.e1. doi: 10.1016/j.gie.2014.03.040. [DOI] [PubMed] [Google Scholar]
  • 26.Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137(1):208–215. doi: 10.1016/j.jtcvs.2008.07.032. [DOI] [PubMed] [Google Scholar]
  • 27.Genovese EA, Dew MA, Teuteberg JJ, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg. 2009;88(4):1162–1170. doi: 10.1016/j.athoracsur.2009.06.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Pagani FD, Miller LW, Russell SD, et al. HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54(4):312–321. doi: 10.1016/j.jacc.2009.03.055. [DOI] [PubMed] [Google Scholar]
  • 29.Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30(2):115–123. doi: 10.1016/j.healun.2010.12.001. [DOI] [PubMed] [Google Scholar]
  • 30.Suarez J, Patel CB, Felker GM, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4(6):779–784. doi: 10.1161/CIRCHEARTFAILURE.111.962613. [DOI] [PubMed] [Google Scholar]
  • 31.Crow S, Milano C, Joyce L, et al. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients. ASAIO J. 2010;56(5):441–445. doi: 10.1097/MAT.0b013e3181e5de0a. [DOI] [PubMed] [Google Scholar]
  • 32.Feldman D, Pamboukian SV, Teuteberg JJ, et al. International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–187. doi: 10.1016/j.healun.2012.09.013. [DOI] [PubMed] [Google Scholar]
  • 33.Katz JN, Adamson RM, John R, et al. TRACE study. Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. J Heart Lung Transplant. 2015;34(12):1542–1548. doi: 10.1016/j.healun.2015.06.018. [DOI] [PubMed] [Google Scholar]
  • 34.Loyaga-Rendon RY, Hashim T, Tallaj JA, et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. ASAIO J. 2015;61(1):107–109. doi: 10.1097/MAT.0000000000000143. [DOI] [PubMed] [Google Scholar]
  • 35.Draper K, Kale P, Martin B, Cordero K, Ha R, Banerjee D. Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant. 2015;34(1):132–134. doi: 10.1016/j.healun.2014.09.013. [DOI] [PubMed] [Google Scholar]
  • 36.Ray R, Kale PP, Ha R, Banerjee D. Treatment of left ventricular assist device-associated arteriovenous malformations with thalidomide. ASAIO J. 2014;60(4):482–483. doi: 10.1097/MAT.0000000000000087. [DOI] [PubMed] [Google Scholar]
  • 37.Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93(5):1534–1540. doi: 10.1016/j.athoracsur.2012.02.035. [DOI] [PubMed] [Google Scholar]
  • 38.Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost. 2015;13(10):1757–1767. doi: 10.1111/jth.13120. [DOI] [PubMed] [Google Scholar]
  • 39.Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24(1):105–109. doi: 10.1016/j.healun.2003.10.018. [DOI] [PubMed] [Google Scholar]
  • 40.Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011;30(8):849–853. doi: 10.1016/j.healun.2011.03.008. [DOI] [PubMed] [Google Scholar]
  • 41.Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343–349. doi: 10.1056/NEJMoa022831. [DOI] [PubMed] [Google Scholar]
  • 42.Heilmann C, Geisen U, Beyersdorf F, et al. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients. Eur J Cardiothorac Surg. 2011;40(6):1328–1333, discussion 1233. doi: 10.1016/j.ejcts.2011.03.021. [DOI] [PubMed] [Google Scholar]
  • 43.Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg. 2008;33(4):679–684. doi: 10.1016/j.ejcts.2007.12.047. [DOI] [PubMed] [Google Scholar]
  • 44.Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395–424. doi: 10.1146/annurev.biochem.67.1.395. [DOI] [PubMed] [Google Scholar]
  • 45.Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262(18):8443–8446. [PubMed] [Google Scholar]
  • 46.Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood. 1987;70(5):1679–1682. [PubMed] [Google Scholar]
  • 47.Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest. 1989;84(1):56–61. doi: 10.1172/JCI114169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Shiltagh N, Kirkpatrick J, Cabrita LD, et al. Solution structure of the major factor VIII binding region on von Willebrand factor. Blood. 2014;123(26):4143–4151. doi: 10.1182/blood-2013-07-517086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87(10):4223–4234. [PubMed] [Google Scholar]
  • 50.Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87(10):4235–4244. [PubMed] [Google Scholar]
  • 51.Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–494. doi: 10.1038/35097008. [DOI] [PubMed] [Google Scholar]
  • 52.Choi H, Aboulfatova K, Pownall HJ, Cook R, Dong JF. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem. 2007;282(49):35604–35611. doi: 10.1074/jbc.M704047200. [DOI] [PubMed] [Google Scholar]
  • 53.Li Y, Choi H, Zhou Z, et al. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost. 2008;6(7):1135–1143. doi: 10.1111/j.1538-7836.2008.02991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood. 1987;69(1):27–32. [PubMed] [Google Scholar]
  • 55.Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83(12):3536–3544. [PubMed] [Google Scholar]
  • 56.Mayadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem. 1989;264(23):13497–13503. [PubMed] [Google Scholar]
  • 57.Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72(6):341–348. doi: 10.1007/s002770050184. [DOI] [PubMed] [Google Scholar]
  • 58.Girma JP, Chopek MW, Titani K, Davie EW. Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain. Biochemistry. 1986;25(11):3156–3163. doi: 10.1021/bi00359a013. [DOI] [PubMed] [Google Scholar]
  • 59.Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol. 1991;113(1):195–205. doi: 10.1083/jcb.113.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Journet AM, Saffaripour S, Wagner DD. Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage. Thromb Haemost. 1993;70(6):1053–1057. [PubMed] [Google Scholar]
  • 61.Bonthron DT, Handin RI, Kaufman RJ, et al. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature. 1986;324(6094):270–273. doi: 10.1038/324270a0. [DOI] [PubMed] [Google Scholar]
  • 62.Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA. 1992;89(8):3531–3535. doi: 10.1073/pnas.89.8.3531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46(2):185–190. doi: 10.1016/0092-8674(86)90735-x. [DOI] [PubMed] [Google Scholar]
  • 64.Brouland JP, Egan T, Roussi J, et al. In vivo regulation of von willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. Arterioscler Thromb Vasc Biol. 1999;19(12):3055–3062. doi: 10.1161/01.atv.19.12.3055. [DOI] [PubMed] [Google Scholar]
  • 65.Tsai HM, Nagel RL, Hatcher VB, Seaton AC, Sussman II. The high molecular weight form of endothelial cell von Willebrand factor is released by the regulated pathway. Br J Haematol. 1991;79(2):239–245. doi: 10.1111/j.1365-2141.1991.tb04528.x. [DOI] [PubMed] [Google Scholar]
  • 66.Counts RB, Paskell SL, Elgee SK. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J Clin Invest. 1978;62(3):702–709. doi: 10.1172/JCI109178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest. 1985;76(4):1491–1500. doi: 10.1172/JCI112129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033–4039. doi: 10.1182/blood-2002-05-1401. [DOI] [PubMed] [Google Scholar]
  • 69.Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007;5(3):583–589. doi: 10.1111/j.1538-7836.2007.02361.x. [DOI] [PubMed] [Google Scholar]
  • 70.Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood. 1987;69(5):1531–1534. [PubMed] [Google Scholar]
  • 71.Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood. 2003;101(7):2637–2645. doi: 10.1182/blood-2002-05-1550. [DOI] [PubMed] [Google Scholar]
  • 72.Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330–1334. doi: 10.1126/science.1170905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Wu T, Lin J, Cruz MA, Dong JF, Zhu C. Force-induced cleavage of single VWFA1A2A3 tridomains by ADAMTS-13. Blood. 2010;115(2):370–378. doi: 10.1182/blood-2009-03-210369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996;88(5):1525–1541. [PubMed] [Google Scholar]
  • 75.Girdhar G, Xenos M, Alemu Y, et al. Device thrombogenicity emulation: a novel method for optimizing mechanical circulatory support device thromboresistance. PLoS One. 2012;7(3):e32463. doi: 10.1371/journal.pone.0032463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Selgrade BP, Truskey GA. Computational fluid dynamics analysis to determine shear stresses and rates in a centrifugal left ventricular assist device. Artif Organs. 2012;36(4):E89–E96. doi: 10.1111/j.1525-1594.2011.01416.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Fraser KH, Zhang T, Taskin ME, Griffith BP, Wu ZJ. A quantitative comparison of mechanical blood damage parameters in rotary ventricular assist devices: shear stress, exposure time and hemolysis index. J Biomech Eng. 2012;134(8):081002. doi: 10.1115/1.4007092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Curtas AR, Wood HG, Allaire PE, McDaniel JC, Day SW, Olsen DB. Computational fluid dynamics modeling of impeller designs for the HeartQuest left ventricular assist device. ASAIO J. 2002;48(5):552–561. doi: 10.1097/00002480-200209000-00019. [DOI] [PubMed] [Google Scholar]
  • 79.Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2(2):141–145. doi: 10.1016/j.jchf.2013.10.008. [DOI] [PubMed] [Google Scholar]
  • 80.Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA. 2007;104(19):7899–7903. doi: 10.1073/pnas.0608422104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Wijeratne SS, Botello E, Yeh HC, et al. Mechanical activation of a multimeric adhesive protein through domain conformational change. Phys Rev Lett. 2013;110(10):108102. doi: 10.1103/PhysRevLett.110.108102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83(8):2171–2179. [PubMed] [Google Scholar]
  • 83.Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood. 2008;111(2):651–657. doi: 10.1182/blood-2007-05-093021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Barg A, Ossig R, Goerge T, et al. Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network. Thromb Haemost. 2007;97(4):514–526. [PubMed] [Google Scholar]
  • 85.Kim J, Zhang CZ, Zhang X, Springer TA. A mechanically stabilized receptor-ligand flex-bond important in the vasculature. Nature. 2010;466(7309):992–995. doi: 10.1038/nature09295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Yago T, Lou J, Wu T, et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest. 2008;118(9):3195–3207. doi: 10.1172/JCI35754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Shankaran H, Neelamegham S. Hydrodynamic forces applied on intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J. 2004;86(1 Pt 1):576–588. doi: 10.1016/S0006-3495(04)74136-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Gogia S, Neelamegham S. Role of fluid shear stress in regulating VWF structure, function and related blood disorders. Biorheology. 2015;52(5-6):319–335. doi: 10.3233/BIR-15061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Singh I, Themistou E, Porcar L, Neelamegham S. Fluid shear induces conformation change in human blood protein von Willebrand factor in solution. Biophys J. 2009;96(6):2313–2320. doi: 10.1016/j.bpj.2008.12.3900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Themistou E, Singh I, Shang C, Balu-Iyer SV, Alexandridis P, Neelamegham S. Application of fluorescence spectroscopy to quantify shear-induced protein conformation change. Biophys J. 2009;97(9):2567–2576. doi: 10.1016/j.bpj.2009.08.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Zheng Y, Chen J, López JA. Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun. 2015;6:7858. doi: 10.1038/ncomms8858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Dayananda KM, Singh I, Mondal N, Neelamegham S. von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood. 2010;116(19):3990–3998. doi: 10.1182/blood-2010-02-269266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Zhang W, Deng W, Zhou L, et al. Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. Blood. 2015;125(3):562–569. doi: 10.1182/blood-2014-07-589507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939–2950. [PubMed] [Google Scholar]
  • 95.Colace TV, Diamond SL. Direct observation of von Willebrand factor elongation and fiber formation on collagen during acute whole blood exposure to pathological flow. Arterioscler Thromb Vasc Biol. 2013;33(1):105–113. doi: 10.1161/ATVBAHA.112.300522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Da Q, Teruya M, Guchhait P, Teruya J, Olson JS, Cruz MA. Free hemoglobin increases von Willebrand factor-mediated platelet adhesion in vitro: implications for circulatory devices. Blood. 2015;126(20):2338–2341. doi: 10.1182/blood-2015-05-648030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Zhou Z, Han H, Cruz MA, López JA, Dong JF, Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost. 2009;101(6):1070–1077. [PubMed] [Google Scholar]
  • 98.Katz JN, Jensen BC, Chang PP, Myers SL, Pagani FD, Kirklin JK. A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy. J Heart Lung Transplant. 2015;34(5):701–709. doi: 10.1016/j.healun.2014.10.002. [DOI] [PubMed] [Google Scholar]
  • 99.Whitson BA, Eckman P, Kamdar F, et al. Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients. Ann Thorac Surg. 2014;97(6):2097–2103. doi: 10.1016/j.athoracsur.2014.02.041. [DOI] [PubMed] [Google Scholar]
  • 100.Ravichandran AK, Parker J, Novak E, et al. Hemolysis in left ventricular assist device: a retrospective analysis of outcomes. J Heart Lung Transplant. 2014;33(1):44–50. doi: 10.1016/j.healun.2013.08.019. [DOI] [PubMed] [Google Scholar]
  • 101.Bartoli CR, Ghotra AS, Pachika AR, Birks EJ, McCants KC. Hematologic markers better predict left ventricular assist device thrombosis than echocardiographic or pump parameters. Thorac Cardiovasc Surg. 2014;62(5):414–418. doi: 10.1055/s-0034-1376891. [DOI] [PubMed] [Google Scholar]
  • 102.Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic fenton reagent. J Biol Chem. 1984;259(23):14354–14356. [PubMed] [Google Scholar]
  • 103.Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115(3):706–712. doi: 10.1182/blood-2009-03-213967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, López JA. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood. 2011;118(19):5283–5291. doi: 10.1182/blood-2011-01-331074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Lancellotti S, De Filippis V, Pozzi N, et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med. 2010;48(3):446–456. doi: 10.1016/j.freeradbiomed.2009.11.020. [DOI] [PubMed] [Google Scholar]
  • 106.Wang Y, Chen J, Ling M, López JA, Chung DW, Fu X. Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation. J Biol Chem. 2015;290(3):1422–1431. doi: 10.1074/jbc.M114.599084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg. 2010;90(4):1263–1269, discussion 1269. doi: 10.1016/j.athoracsur.2010.04.099. [DOI] [PubMed] [Google Scholar]
  • 108.Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56(15):1207–1213. doi: 10.1016/j.jacc.2010.05.016. [DOI] [PubMed] [Google Scholar]
  • 109.Goda M, Jacobs S, Rega F, et al. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump. J Heart Lung Transplant. 2013;32(5):539–545. doi: 10.1016/j.healun.2013.02.006. [DOI] [PubMed] [Google Scholar]
  • 110.Restle DJ, Zhang DM, Hung G, et al. Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation. Artif Organs. 2015;39(7):569–575. doi: 10.1111/aor.12428. [DOI] [PubMed] [Google Scholar]
  • 111.Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail. 2010;3(6):675–681. doi: 10.1161/CIRCHEARTFAILURE.109.877597. [DOI] [PubMed] [Google Scholar]
  • 112.Van Belle E, Rauch A, Vincentelli A, et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res. 2015;116(7):1193–1201. doi: 10.1161/CIRCRESAHA.116.305046. [DOI] [PubMed] [Google Scholar]
  • 113.Davis ME, Haglund NA, Tricarico NM, Matafonov A, Gailani D, Maltais S. Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation. ASAIO J. 2015;61(1):e1–e4. doi: 10.1097/MAT.0000000000000157. [DOI] [PubMed] [Google Scholar]
  • 114.Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53(23):2162–2167. doi: 10.1016/j.jacc.2009.02.048. [DOI] [PubMed] [Google Scholar]
  • 115.Baghai M, Heilmann C, Beyersdorf F, et al. Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices. Eur J Cardiothorac Surg. 2015;48(3):421–427. doi: 10.1093/ejcts/ezu510. [DOI] [PubMed] [Google Scholar]
  • 116.Michiels JJ, Berneman Z, Gadisseur A, et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost. 2006;12(4):397–420. doi: 10.1177/1076029606293422. [DOI] [PubMed] [Google Scholar]
  • 117.Buzza MS, Dyson JM, Choi H, et al. Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J Biol Chem. 2008;283(33):22498–22504. doi: 10.1074/jbc.M709080200. [DOI] [PubMed] [Google Scholar]
  • 118.Hollestelle MJ, Lai KW, van Deuren M, et al. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS One. 2011;6(9):e24216. doi: 10.1371/journal.pone.0024216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Tersteeg C, de Maat S, De Meyer SF, et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation. 2014;129(12):1320–1331. doi: 10.1161/CIRCULATIONAHA.113.006727. [DOI] [PubMed] [Google Scholar]
  • 120.Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains. J Biol Chem. 1986;261(33):15679–15689. [PubMed] [Google Scholar]
  • 121.Federici AB, Rand JH, Bucciarelli P, et al. Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84(2):345–349. [PubMed] [Google Scholar]
  • 122.Sadler JE, Budde U, Eikenboom JC, et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114. doi: 10.1111/j.1538-7836.2006.02146.x. [DOI] [PubMed] [Google Scholar]
  • 123.Stulak JM, Lee D, Haft JW, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant. 2014;33(1):60–64. doi: 10.1016/j.healun.2013.07.020. [DOI] [PubMed] [Google Scholar]
  • 124.Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87(4):1234–1240. doi: 10.1172/JCI115124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988;71(5):1366–1374. [PubMed] [Google Scholar]
  • 126.Auton M, Sowa KE, Smith SM, Sedlák E, Vijayan KV, Cruz MA. Destabilization of the A1 domain in von Willebrand factor dissociates the A1A2A3 tri-domain and provokes spontaneous binding to glycoprotein Ibalpha and platelet activation under shear stress. J Biol Chem. 2010;285(30):22831–22839. doi: 10.1074/jbc.M110.103358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78(6):1456–1461. doi: 10.1172/JCI112736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987;69(2):625–628. [PubMed] [Google Scholar]
  • 129.Turner NA, Moake JL, Kamat SG, et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation. 1995;91(5):1354–1362. doi: 10.1161/01.cir.91.5.1354. [DOI] [PubMed] [Google Scholar]
  • 130.Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 2001;98(12):3340–3345. doi: 10.1182/blood.v98.12.3340. [DOI] [PubMed] [Google Scholar]

Articles from Blood are provided here courtesy of The American Society of Hematology

RESOURCES